Year: 2023
Type: article
Abstract: To the Editor: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung disease (ILD) with a poor prognosis (1).In 2014, two antifibrotic agents, nintedanib and pirfenidone, were approved by the U.S. Food and Drug Administration to slow the progression of the disease (2-4).Subsequently, studies among patients enrolled in IPF registries reported antifibrotic agent uptake rates among eligible patients with IPF as high as 70% (5, 6), whereas adoption among insured patients in the general population and veterans was lower (approximately 17-25%) (7, 8).The uptake of and factors associated with antifibrotic agent use in socioeconomically diverse populations is unclear.We evaluated the adoption of antifibrotic medications for patients with IPF in a large, multicenter, all-payer database.
Institution: Boston University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Awards: G1002436950, Automated detection and prediction of atrial fibrillation during sepsis, Evaluating Routine Opioid Use during Acute Respiratory Failure, Corticosteroids for Acute Exacerbations of Idiopathic Pulmonary Fibrosis: Patterns and Outcomes, ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center, Institutional Career Development, Prolonged mechanical ventilation: patterns of post-acute care and patient outcomes, G477853788, G5779905480, Biology of the Lung: A Multidisciplinary Program, Utilizing induced pluripotent stem cells to study the role of alveolar type 2 cell dysfunction in pulmonary fibrosis
OpenAlex ID: W4387934041